Want to see TLX full AI Analyst Report?
Top Page
Telix Pharmaceuticals Limited Unsponsored ADR
(NASDAQ:TLX)
Select Model
Select Model
Rating:62Neutral
Price Target:
$12.50
Action:N/A
Date:09/23/26
The score is anchored by mixed financial quality (recent return to losses, higher leverage, and negative 2025 cash flow) despite exceptional top-line growth. Offsetting this, technicals are constructive with the stock above major moving averages, and the latest earnings call conveyed strong momentum and confident guidance. Valuation remains a key constraint given the very high P/E and no dividend support.
Positive Factors
Strong revenue and earnings growth
Strong first-half revenue, EBITDA and net profit growth indicates that Telix is converting commercial demand into improving operating performance. Continued execution across precision-medicine products can strengthen internal funding capacity and support growth over the next several quarters.
Negative Factors
Higher leverage and weaker cash generation
Recent negative operating and free cash flow, together with debt exceeding equity, increases reliance on external funding while the company invests for growth. This can limit financial flexibility and make execution more sensitive to delays, spending requirements or weaker commercial conversion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and earnings growth
Strong first-half revenue, EBITDA and net profit growth indicates that Telix is converting commercial demand into improving operating performance. Continued execution across precision-medicine products can strengthen internal funding capacity and support growth over the next several quarters.
Read all positive factors
Telix Pharmaceuticals Limited Unsponsored ADR (TLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.01B
Dividend YieldN/A
Average Volume (3M)289.64K
Price to Earnings (P/E)116.2
Beta (1Y)1.54
Revenue Growth33.78%
EPS Growth198.49%
CountryUS
Employees1,152
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.14
Shares Outstanding339,892,360
10 Day Avg. Volume573,302
30 Day Avg. Volume289,640
Financial Highlights & Ratios
PEG Ratio2.93
Price to Book (P/B)6.09
Price to Sales (P/S)3.15
P/FCF Ratio-45.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.08
Revenue Forecast (FY)$980.31M
Telix Pharmaceuticals Limited Unsponsored ADR Business Overview & Revenue Model
Company Description
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Ther...
How the Company Makes Money
Telix generates revenue primarily by selling radiopharmaceutical products and related services. Its revenue model includes: (1) Commercial product sales: Revenue from the manufacture and sale of approved radiopharmaceuticals supplied to healthcare...
Telix Pharmaceuticals Limited Unsponsored ADR Earnings Call Summary
Earnings Call Date:Aug 19, 2026
(Q2-2026)
| Next Earnings Date:Feb 19, 2027
Earnings Call Sentiment Positive
The call was strongly positive, supported by 22% group revenue growth, 146% EBITDA growth, 27% Precision Medicine growth, consecutive PSMA market-share gains, successful Gozellix adoption, a strengthened cash position and broad clinical and regulatory progress. The main negatives were Zircaix's corrected complete response letter and related manufacturing deficiencies, the uncertain Pixlumi review timeline, and the fact that the existing PSMA market is already approximately two-thirds penetrated. Overall, the highlights significantly outweigh the lowlights.Positive Updates
Strong First-Half Financial Performance
H1 2026 revenue reached $477 million, up 22% compared with H1 2025. EBITDA improved 146% year-on-year to $52 million, while net profit after tax increased to $38 million. Management attributed the performance to robust commercial execution, strong demand for precision medicine products and continued control of operating expenditure.
Negative Updates
Zircaix Corrected Complete Response Letter
Telix received a corrected complete response letter from the FDA for Zircaix. The company said the resubmission must fully address outstanding items, particularly third-party manufacturing deficiencies, before filing.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong First-Half Financial Performance
H1 2026 revenue reached $477 million, up 22% compared with H1 2025. EBITDA improved 146% year-on-year to $52 million, while net profit after tax increased to $38 million. Management attributed the performance to robust commercial execution, strong demand for precision medicine products and continued control of operating expenditure.
Read all positive updates
Company Guidance
For 2026, Telix maintained full year revenue guidance of between $950 million and $970 million, expects that to land at the upper end of the range, and expects continued growth in excess of 20% year-on-year of its Precision Medicine business; full-time guidance does not reflect unapproved products, providing the potential for upside. R&D guidance was updated to a range of $230 million to $270 million. Management said Zircaix resubmission in the next month or two would be a reasonable assumption, while Pixlumi’s standardized review process is around an 18-month process and can go a little bit faster, a little bit slower depending on clock stops and review times.Telix Pharmaceuticals Limited Unsponsored ADR Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.31B | 1.21B | 783.21M | 502.55M | 160.10M | 7.60M |
| Gross Profit | 684.05M | 640.23M | 509.68M | 314.39M | 94.93M | 5.05M |
| EBITDA | 46.22M | 79.83M | 98.23M | 22.97M | -92.84M | -70.07M |
| Net Income | 48.26M | -10.69M | 49.92M | 5.21M | -104.08M | -80.51M |
Balance Sheet | ||||||
| Total Assets | 1.97B | 1.77B | 1.52B | 398.30M | 255.35M | 109.81M |
| Cash, Cash Equivalents and Short-Term Investments | 363.63M | 212.53M | 710.35M | 123.24M | 116.33M | 22.04M |
| Total Debt | 837.03M | 699.77M | 581.45M | 17.45M | 10.45M | 2.54M |
| Total Liabilities | 1.26B | 1.15B | 948.22M | 249.39M | 175.35M | 106.17M |
| Stockholders Equity | 703.96M | 622.27M | 568.21M | 148.91M | 80.01M | 2.16M |
Cash Flow | ||||||
| Free Cash Flow | -86.70M | -82.80M | 28.71M | 14.21M | -71.01M | -60.67M |
| Operating Cash Flow | -19.19M | -25.93M | 43.03M | 23.88M | -63.97M | -59.33M |
| Investing Cash Flow | -90.00M | -428.79M | -135.17M | -25.49M | -17.00M | -2.73M |
| Financing Cash Flow | 170.32M | -5.58M | 638.92M | 10.19M | 174.96M | 2.85M |
Telix Pharmaceuticals Limited Unsponsored ADR Technical Analysis
Negative
―
Price Trends
11.31
Negative
10.85
Positive
9.59
Positive
Market Momentum
0.13
Positive
46.74
Neutral
31.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLX, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 11.72, equal to the 50-day MA of 11.31, and equal to the 200-day MA of 9.59, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 31.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TLX.
Telix Pharmaceuticals Limited Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $4.01B | 116.21 | 7.11% | ― | 33.78% | 198.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $2.09B | -21.03 | 81.78% | ― | 100.27% | 39.90% | |
52 Neutral | $1.74B | -59.29 | 31.23% | ― | ― | ― | |
52 Neutral | $1.40B | -13.96 | -138.12% | ― | ― | -115.15% | |
49 Neutral | $1.67B | -174.93 | -2.35% | ― | 20.19% | ― | |
45 Neutral | $1.33B | -4.75 | -47.04% | ― | -65.40% | -164.71% |
* General Sector Average
TLX
Telix Pharmaceuticals Limited Unsponsored ADR
11.27
1.16
11.47%
URGN
Urogen Pharma
41.63
24.37
141.19%
IMTX
Immatics
8.60
1.55
21.99%
IMCR
Immunocore Holdings
31.54
-2.54
-7.45%
NBTX
Nanobiotix
35.24
20.49
138.92%
DRTS
Alpha Tau
14.52
10.36
249.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.